Brain regions vulnerable and resistant to aging without Alzheimer's disease
- PMID: 32726311
- PMCID: PMC7390259
- DOI: 10.1371/journal.pone.0234255
Brain regions vulnerable and resistant to aging without Alzheimer's disease
Abstract
'Normal aging' in the brain refers to age-related changes that occur independent of disease, in particular Alzheimer's disease. A major barrier to mapping normal brain aging has been the difficulty in excluding the earliest preclinical stages of Alzheimer's disease. Here, before addressing this issue we first imaged a mouse model and learn that the best MRI measure of dendritic spine loss, a known pathophysiological driver of normal aging, is one that relies on the combined use of functional and structural MRI. In the primary study, we then deployed the combined functional-structural MRI measure to investigate over 100 cognitively-normal people from 20-72 years of age. Next, to cover the tail end of aging, in secondary analyses we investigated structural MRI acquired from cognitively-normal people, 60-84 years of age, who were Alzheimer's-free via biomarkers. Collectively, the results from the primary functional-structural study, and the secondary structural studies revealed that the dentate gyrus is a hippocampal region differentially affected by aging, and that the entorhinal cortex is a region most resistant to aging. Across the cortex, the primary functional-structural study revealed and that the inferior frontal gyrus is differentially affected by aging, however, the secondary structural studies implicated other frontal cortex regions. Together, the results clarify how normal aging may affect the brain and has possible mechanistic and therapeutic implications.
Conflict of interest statement
I have read the journal's policy and the authors of this paper have the following competing interests: FAP is a consultant for and has equity in Imij Technologies. SAS serves on the scientific advisory board of Meira GTX, recently came off the scientific advisory board of Denali Theraputics, and has equity in Imij Technologies. AMB is a scientific consultant to Cognition theraptueics, Keystone Heart, and MedAvante-ProPhase, and recently served on an advisory board for F. Hoffmann-La Roche and Keystone Heart. XF, FAP, SAS and AMB have either granted patents or applications in neuroimaging for which no royalties are received. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
